|Bid||39.20 x 200|
|Ask||39.99 x 500|
|Day's Range||39.81 - 42.44|
|52 Week Range||13.50 - 45.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.17|
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 08, 2018-- CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that ...
Neither the CRISPR/Cas9 start-up nor its gene-editing peers had much to say last month, but it only took a suggestion of positive signs from elsewhere to send them rocketing higher.
Intellia Therapeutics, Crispr Therapeutics and Editas Medicine are at the forefront of the new CRISPR gene editing technology, which could cure thousands of diseases.
Crispr Therapeutics’ largest shareholder just invested another $12 million in the Swiss developer of gene-based medicines. Bayer disclosed that on Jan. 5 a subsidiary bought another 527,500 shares of Crispr (CRSP) for $22.75 each in a public offering. Bayer’s total ownership now stands at 5.71 million shares.
Gene editing refers to the process of insertion, deletion or replacement of DNA at a specific site in the genome of an organism or cell. Investors have a few opportunities to gain exposure to companies ...
China is taking the lead in the global race to perfect gene therapies. Scientists have genetically engineered the cells of at least 86 cancer and HIV patients in the country using Crispr-Cas9 technology since 2015, the Wall Street Journal reports (paywall). Although no formal scientific papers have been written about these experiments, doctors told journalists…
U.S. scientists helped devise the Crispr biotechnology tool that has captured global attention for its potential to treat incurable diseases. The first to test it in humans are Chinese doctors, who don’t ...
CRISPR Therapeutics AG (CRSP) was a big mover last session, as the company saw its shares more than 12% on the day amid huge volumes.
While most secondary offerings would bring down the price of the stock, this case is different and shareholders are cheering this dilution because it might bring about something greater.
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 04, 2018-- CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the ...